Compare Wahed FTSE USA Shariah ETF (HLAL) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wahed FTSE USA Shariah ETF vs Incyte Corporation — how do they compare? Wahed FTSE USA Shariah ETF trades at $73.25, while Incyte Corporation trades at $120.45 (market cap $24.65B). The key difference: Wahed FTSE USA Shariah ETF is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals.
| HLAL | INCY | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $73.60 | $129.93 |
52-Week Low | $55.52 | $81.61 |
Market Cap | — | $24.65B |
Enterprise Value | — | $20.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HLAL stock trades at $73.14, up 0.71% with strong bullish technical signals from moving averages. The stock shows positive momentum with key indicators suggesting upward trend continuation. Recent dividend announcement of $0.02 scheduled for June 2026 provides long-term income potential.
The stock presents a bullish technical outlook with fundamental analysis limited by incomplete financial data. Investment opportunity lies in the strong technical momentum, though risks include potential overbought conditions and lack of current financial metrics for comprehensive valuation assessment.
Incyte Corporation (INCY) trades at $120.56, up 1.84% on the day, near its 52-week high of $120.70. The stock shows a bullish technical trend with strong earnings beats in Q1 and Q2 2026, including Q2 EPS of $3.09 versus $2.15 expected. Revenue growth accelerated to $5.14 billion in 2025, with a net income margin of 27.71%. Recent news highlights EU approval for Opzelura and a raised 2026 revenue outlook, fueling positive momentum.
The outlook remains favorable with analyst consensus at Buy and a $122.82 price target, though risks include reliance on key drugs like Jakafi and competitive pressures. Earnings growth and pipeline advancements support upside, but investors should monitor execution against guidance and regulatory developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Wahed FTSE USA Shariah ETF
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
